Aarhus firm Draupnir Bio receives DKK 225 million from well-known venture funds
Draupnir Bio, which is developing a pill for blood clots in the heart, has received DKK 225 million from four european venture funds including Novo Seeds.
BY KEVIN GRØNNEMANN
There is good reason to celebrate at the two and a half year old Aarhus-based company Draupnir Bio: The company has just received DKK 225 million (USD 33.4 million) from a number of venture funds.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
